Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third-Party Payers Have No Class: Zyprexa Ruling Cites Non-Uniform Pricing In Tossing Out Group Challenge

Executive Summary

Third-party payers had hoped to obtain billions in damages in a suit claiming Eli Lilly & Co. misrepresented the side effects and safety of its antipsychotic Zyprexa (olanzapine). But an appeals court reversed their class certification and also found that they could not proceed with their main theory of damages as individual plaintiffs.
Advertisement

Related Content

Lilly Will Not Settle Zyprexa Overpricing Suit; Judge Finds Evidence Of Fraud
Lilly Will Not Settle Zyprexa Overpricing Suit; Judge Finds Evidence Of Fraud

Topics

Advertisement
UsernamePublicRestriction

Register

PS052637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel